Onkogeny RAS – prediktivní molekulární marker u kolorektálního karcinomu
Authors:
J. Tomášek 1,2; J. Berkovcová 2,3
Authors‘ workplace:
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
1; LF MU, Brno
2; 1. úsek diagnostické bioptické patologie, Masarykův onkologický ústav, Brno
3
Published in:
Klin Onkol 2013; 26(5): 366-367
Category:
Oncology Highlights
Sources
1. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93(14): 1062–1074.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2013 Issue 5
- Metamizole vs. Tramadol in Postoperative Analgesia
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
- Possibilities of Using Metamizole in the Treatment of Acute Primary Headaches
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
Most read in this issue
- Management of Infections in Palliative and Terminal Cancer Care
- Chylous Ascites as a Serious Complication of the Neuroendocrine Tumor of Ileum – Case Report
- Nephroblastoma – 30-Years Period of its Treatment in the University Hospital Motol, Prague
- Onkogeny RAS – prediktivní molekulární marker u kolorektálního karcinomu